RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/21399669http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/21399669http://www.w3.org/2000/01/rdf-schema#comment"HLA-G molecules are HLA class Ib antigens characterized by tolerogenic and immunoinhibitory functions. The HLA-G 14-bp insertion/deletion (ins/del) polymorphism controls protein expression and seems to be implicated in both MTX treatment response and SCT outcome. The aim of our study is to evaluate the role of HLA-G 14 bp polymorphism in subjects affected by hematological malignancies undergoing allo-SCT and receiving MTX therapy for GvHD prophylaxis. We performed a retrospective analysis of HLA-G 14 bp polymorphism using a specific PCR in 47 recipients and in their respective donors, and evaluated the correlation with the incidence of aGvHD, OS and disease-free survival (DFS) after allo-SCT. We did not observe any correlation between this polymorphism and the risk of aGvHD occurrence. On the contrary, we found that the recipients with a 14 bp ins/14 bp ins genotype were characterized by a lower OS and DFS in univariate and multivariate analysis (OS=OR: 3.235; DFS=OR: 3.302). These data indicate a role for recipient HLA-G 14 bp polymorphism in allo-SCT immunotolerance status and follow-up."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.org/dc/terms/identifier"doi:10.1038/bmt.2011.40"xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/author"Leone G."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/author"Rizzo R."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/author"Bellesi S."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/author"Marietti S."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/author"Sica S."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/author"Baricordi O.R."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/author"Chiusolo P."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/author"Stignani M."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/author"De Ritis D."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/author"Giammarco S."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/author"Metafuni E."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/author"Piccirillo N."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/date"2012"xsd:gYear
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/name"Bone Marrow Transplant"xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/pages"120-124"xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/title"The role of HLA--G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis."xsd:string
http://purl.uniprot.org/citations/21399669http://purl.uniprot.org/core/volume"47"xsd:string
http://purl.uniprot.org/citations/21399669http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/21399669
http://purl.uniprot.org/citations/21399669http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/21399669
http://purl.uniprot.org/uniprot/#_A0A0H4M9X9-mappedCitation-21399669http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/21399669
http://purl.uniprot.org/uniprot/#_A0A0H4M9Y0-mappedCitation-21399669http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/21399669
http://purl.uniprot.org/uniprot/#_A0A0H4M9Y1-mappedCitation-21399669http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/21399669